Charles River Laboratories International, INC Form 4 insider transactions

Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories International, Inc., reported the acquisition of 12,239 restricted stock units and the subsequent disposal of 283 shares for tax withholding purposes.

Victoria L. Creamer, EVP & Chief People Officer of Charles River Laboratories, reported the acquisition of 6,252 common shares as restricted stock units and the disposition of 120 shares for tax purposes.

Charles River Laboratories' Chairman, President, and CEO, James C. Foster, reported the acquisition of 17,253 shares of common stock as restricted stock units and an internal transfer of shares, increasing his direct beneficial ownership.

Flavia Pease, Corporate Executive VP & CFO of Charles River Laboratories International, Inc., reported the disposition of 331 shares of common stock over two days to satisfy tax withholding obligations.

Shannon M. Parisotto, CEVP of Discovery and Safety Assessment at Charles River Laboratories, reported the disposition of common stock shares totaling 213 units over three days in late May 2025, primarily for tax withholding purposes.

Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories, reported the disposition of common stock to cover tax obligations related to equity awards.

Michael G. Knell, CSVP & Chief Accounting Officer of Charles River Laboratories, reported the disposition of 112 common shares over three days in May 2025 to satisfy tax withholding obligations.

Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories, reported the disposition of 640 shares of common stock over three days in May 2025, primarily for tax withholding purposes.

Victoria L. Creamer, EVP & Chief People Officer at Charles River Laboratories, reported the disposition of common stock shares to cover tax withholding obligations related to equity awards.

Craig B. Thompson, a Director at Charles River Laboratories International, Inc., reported the acquisition of 946 shares of common stock and 2,076 stock options.

Charles River Laboratories International, Inc. Director George Llado Sr. has acquired 1,465 shares of common stock and 2,076 stock options as part of compensation, vesting over the next year.

Charles River Laboratories International, Inc. Director Martin Mackay reported the acquisition of common stock and stock options, primarily as compensation for director services, increasing his beneficial ownership in the company.

Reshema Kemps-Polanco, a Director at Charles River Laboratories International, Inc., acquired 946 restricted stock units, an additional 630 restricted stock units in lieu of director service fees, and 2,076 stock options, all priced at $134.98 per share, as part of her compensation.

Virginia M. Wilson, a Director at Charles River Laboratories International, Inc. (CRL), reported the acquisition of common stock and stock options valued at $134.98 per share, aligning her interests with shareholders.

Nancy C. Andrews, a Director at Charles River Laboratories International, Inc., has acquired 946 shares of common stock as restricted stock units and 2,076 stock options, aligning her interests with shareholders.

Director George Massaro of Charles River Laboratories sold common stock in multiple transactions on May 15, 2025, under a pre-arranged 10b5-1 trading plan.

Director George Massaro of Charles River Laboratories sold a portion of his common stock holdings on May 14, 2025, under a pre-arranged 10b5-1 trading plan.

Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories, sold 500 shares of common stock at a price of $145.41 on May 13, 2025.

Flavia Pease, Corporate Executive VP & CFO of Charles River Laboratories, disposed of 889 shares of common stock on May 2, 2025, to cover tax obligations.

Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories, reported disposing of 430 shares of common stock on February 25, 2025.

James C. Foster, CEO of Charles River Laboratories, reports the acquisition of 6,075 shares of common stock and a transfer of 20,000 shares to a GRAT account.

Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories, purchased 1,514 shares of common stock at $164.63 per share on February 20, 2025.

Joseph W. LaPlume, EVP of Corporate Strategy & Development at Charles River Laboratories, sold 4,400 shares of common stock on February 20, 2025.

Corporate Executive VP & CFO of Charles River Laboratories, Flavia Pease, reports the acquisition of 2,704 shares and the disposal of 914 shares of common stock on January 31, 2025.

James C. Foster, Chairman, President, and CEO of Charles River Laboratories, reports acquisition and disposal of company stock on January 31, 2025.

Joseph W. LaPlume, EVP at Charles River Laboratories, reports acquisition and disposal of company stock on January 31, 2025.

Shannon M. Parisotto, a CEVP at Charles River Laboratories, reported transactions involving company stock, including the acquisition of shares through performance-based awards and a transfer to Karpathos Investments LLC.

Michael Gunnar Knell, CSVP & Chief Accounting Officer of Charles River Laboratories, reports acquisition of shares due to performance share unit awards and disposition of shares for tax purposes.

Victoria Creamer, EVP & Chief People Officer at Charles River Laboratories, reports acquisition of shares through performance share unit awards and disposition of shares to cover tax obligations.

Corporate Executive VP & COO of Charles River Laboratories, Birgit Girshick, reports acquisition of shares through performance share unit awards and disposition of shares to cover tax obligations.